• Molecular Cancer Biology Program
• HBGP - Helsinki Biomedical Graduate Program
• GPBM -
  Helsinki Graduate Program in Biotechnology and Molecular Biology

Contact Information:

Pirjo Laakkonen
M.D., Ph.D.
Academy Fellow
Molecular Cancer Biology Program
Biomedicum Helsinki
PO Box 63 (Haartmaninkatu 8)
FI-00014 University of Helsinki
Finland

Tel. +358 9 191 25537
Fax. +358 9 191 25610

e-mail :
firstname.surname@helsinki.fi

• Sarek, G., Enbäck, J., Järviluoma, A., Haas, J., Gessain, A., Laakkonen, P.* and Ojala, PM*. 2012. Viral lytic replication compromises apoptotic response to p53 reactivation in KSHV lymphomas. Oncogene in press. *Corresponding author
  
  
• Nummela, P., Lammi, J., Soikkeli, J., Saksela, O., Laakkonen, P. and Hölttä, E. 2012. Transforming Growth Factor Beta-induced (TGFBI) is an Anti-adhesive Protein Regulating the Invasive Growth of Melanoma Cells. Am. J. Pathol. in press.
  
  
• Karhemo, P-R., Rivinoja, A., Lundin, J., Hyvönen, M., Chernenko, A., Lammi, J., Sihto, H., Lundin, M., Heikkilä, P., Joensuu, H., Bono, P. and Laakkonen, P. 2011. An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancer. Am. J. Pathol. 179(2):1004-14.
  
  
• Rivinoja, A and Laakkonen, P. 2011. Identification of homing peptides using the in vivo phage display technology. Methods Mol. Biol. 683:401-415.
  
  
• Laakkonen, P. and Vuorinen, K. 2010. Homing peptides as targeted delivery vehicles. Integr. Biol. (Camb) 2(7-8):326-337.
  
  
• Peltonen, K., Colis, L., Liu, H., Jäämaa, S., Moore, H., Enbäck, J., Laakkonen, P., Vaahtokari, A., Jones, RJ., af Hällström, TM. and Laiho, M. 2010. Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents. PLoS One Sep 27;5(9):e12996.
  
  
• D'Amico, G., Korhonen, E., Waltari, M., Saharinen, P., Laakkonen, P. and Alitalo, K. 2010. Loss of endothelial Tie1 receptor impairs lymphatic vessel development. Arterioscler Thromb Vasc Biol. 30(2):207-9. Epub 2009 Nov 12.
  
  
• Laakkonen, P*., Zhang, L. and Ruoslahti, E. 2008. Peptide targeting of lymph vessels. In: The Lymphatic Continuum Revisited. Stanley G. Rockson, ed., Ann. N.Y. Acad. Sci. 1131:37-43. *Corresponding author
  
  
• Hautala, L., Koistinen, R., Seppälä, M., Butsow, R., Stenman, U-H., Laakkonen, P. and Koistinen, H. 2008. Glycodelin reduces breast cancer growth in vivo. Int. J. Cancer 123:2279-2284.
  
  
• Tammela, T., Zarkada, G., Wallgard, E., Murtomäki, A., Suchting, S., Wirzenius, M., Waltari, M., Hellström, M., Schomber, T., Peltonen, R., Freitas, C., Duarte, A., Isoniemi, H., Laakkonen, P., Christofori, G., Ylä-Herttuala, S., Shibuya, M., Pytowski, B., Eichmann, A., Betsholtz, C., and Alitalo, K. 2008. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454:656-660.
  
  
• Petrova, T.V., Bono, P., Holnthoner, W., Chesnes, J., Pytowski, P., Sihto, H., Laakkonen, P., Heikkilä, P., Joensuu, H. and Alitalo, K. 2008. VEGFR-3 expression is restricted to blood and lymphatic vessels in solid tumors. Cancer Cell 13:554-556.
  
  
• Enbäck, J. and Laakkonen, P. 2007. Tumour-homing peptides: tools for targeting, imaging and destruction. Biochem Soc Trans. Aug;35(Pt 4):780-3.
  
  
• Laakkonen, P., Waltari, M., Holopainen, T., Takahashi, T., Pytowski, B., Steiner, P., Hicklin, D., Persaud, K., Tonra, J.R., Witte, L. and Alitalo, K. 2007. Vascular endothelial growth factor receptor 3 (VEGFR-3) is involved in tumor angiogenesis and growth. Cancer Res. 67:593-599.
  
  
• Laakkonen, P. and Ruoslahti, E. 2006. Selective delivery to vascular addresses: In vivo applications of cell type-specific CPPs. In: Cell-Penetrating Peptides, 2nd Edition, Ulo Langel, ed., CRC Press.
  
  
• Laakkonen, P., Akerman, M., Biliran, H., Yang, M., Ferrer, F., Karpanen, T., Hoffman, R. and Ruoslahti, E. 2004. Anti-tumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc. Natl. Acad. Sci. USA 101:9381-9386.
  
  
• Joyce, J.*, Laakkonen, P.*, Bernasconi, M., Berger, G., Ruoslahti, E. and Hanahan, D. 2003. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 4:393-403. *Equal contribution.
  
  
• Åkerman, M.E., Chan, W.C.W, Laakkonen, P., Bhatia, S.N. and Ruoslahti, E. 2002. Nanocrystal targeting in vivo. Proc. Natl. Acad. Sci. USA 99:12617-12621.
  
  
• Laakkonen, P., Porkka, K., Hoffman, J.A. and Ruoslahti, E. 2002. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat. Med. 8:751-755.
  

Page updated March 21, 2012

Mail to Webmaster